scispace - formally typeset
Search or ask a question
Journal ArticleDOI

Significance of CSF NfL and tau in ALS

TL;DR: The findings that higher CSF NfL levels and a reduced ptau/ttau ratio are more associated with clinical UMN involvement and with reduced CST FA offer strong converging evidence that both are markers of central motor degeneration.
Abstract: Cerebrospinal fluid (CSF) neurofilament light chain (NfL) has emerged as putative diagnostic biomarker in amyotrophic lateral sclerosis (ALS), but it remains a matter of debate, whether CSF total tau (ttau), tau phosphorylated at threonine 181 (ptau) and the ptau/ttau ratio could serve as diagnostic biomarker in ALS as well Moreover, the relationship between CSF NfL and tau measures to further axonal and (neuro)degeneration markers still needs to be elucidated Our analysis included 89 ALS patients [median (range) age 63 (33-83) years, 61% male, disease duration 10 (02-190) months] and 33 age- and sex-matched disease controls [60 (32-76), 49%] NfL was higher and the ptau/ttau ratio was lower in ALS compared to controls [8343 (1795-35,945) pg/ml vs 1193 (612-2616), H(1) = 708, p < 0001; mean (SD) 017 (004) vs 02 (003), F(1) = 143, p < 0001], as well as in upper motor neuron dominant (UMND, n = 10) compared to classic (n = 46) or lower motor neuron dominant ALS [n = 31; for NfL: 16,076 (7447-35,945) vs 8205 (2651-35,138) vs 8057 (1795-34,951)], Z ≥ 25, p ≤ 001; for the ptau/ttau ratio: [013 (004) vs 017 (004) vs 018 (003), p ≤ 002] In ALS, NfL and the ptau/ttau ratio were related to corticospinal tract (CST) fractional anisotropy (FA) and radial diffusivity (ROI-based approach and whole-brain voxelwise analysis) Factor analysis of mixed data revealed a co-variance pattern between NfL (factor load - 06), the ptau/ttau ratio (07), CST FA (08) and UMND ALS phenotype (- 28) NfL did not relate to any further neuroaxonal injury marker (brain volumes, precentral gyrus thickness, peripheral motor amplitudes, sonographic cross-sectional nerve area), but a lower ptau/ttau ratio was associated with whole-brain gray matter atrophy and widespread white matter integrity loss Higher NfL baseline levels were associated with greater UMN disease burden, more rapid disease progression, a twofold to threefold greater hazard of death and shorter survival times The findings that higher CSF NfL levels and a reduced ptau/ttau ratio are more associated with clinical UMN involvement and with reduced CST FA offer strong converging evidence that both are markers of central motor degeneration Furthermore, NfL is a marker of poor prognosis, while a low ptau/ttau ratio indicates extramotor pathology in ALS

Summary (2 min read)

Clinical phenotypes

  • Clinical phenotypes were classified according to recent specifications [3, 4].
  • The diagnostic criteria for PLS required a period of at least 4 years in which there were only UMN signs on examination.
  • Other conditions that mimic PLS, such as hereditary spastic paraplegia (HSP) were excluded by appropriate investigations [7].
  • To differentiate this condition from early limb-onset ALS, the authors specified that LMN involvement must be the predominant finding for at least 12 months after the symptom onset.

Data availability

  • CSF data were on hand for all ALS patients, of those 89 cases, 58 (69%) and 13 (15%) patients, respectively, have already been included in their previous cross-sectional and longitudinal peripheral nerve sonography ALS studies [3, 9, 10].
  • Out of the 84 patients with available baseline ALSFRS-R scores, longitudinal ALSFRS-R scoring was performed in n=71 cases (80%) with at least two follow-ups and n=46 cases (52%) with at least three follow-ups.

CSF measures

  • CSF biomarkers were measured with commercially available ELISA (for NfL: NF-light® ELISA, IBL International GmbH, Hamburg, Germany; for total tau [ttau] or ptau: Innotest hTauAg or Innotest p-Tau, Innogenetics, Ghent, Belgium), following the instructions provided by the manufacturer.
  • To assess the performance of the NfL assay the authors determined the intra-assay coefficient of variability (CV; =reproducibility, within-assay performance) and the inter-assay CV (=repeatability, between-assay performance) [11].
  • CV was calculated using the root mean square method, described e.g. in [19].
  • CSF samples of 2 controls and four ALS patients were measured twice on the first assay, and procedure was repeated 24 hours later taking a second assay.
  • Detailed CSF NfL values of each sample are given in Supplemental Table 1.

3T MRI measures of the brain

  • All MRI scans were performed on the same Siemens Verio 3 T system (Siemens Medical Systems, Erlangen, Germany) with a 32-channel head coil.
  • Diffusion gradients were applied along 30 non-collinear directions with b = 1000 s/mm2, one scan without diffusion weighting (b = 0 s/mm2) was also acquired.
  • A T2-weighted FLASH sequence was acquired during the same session to investigate the presence of white matter hyperintensities.
  • The original b-matrix was reoriented using an in-house script to adjust it for rotations induced by the previous transformations.
  • The analyses were performed employing tract-based spatial statistics [16] that warped all the FA images to the FMRIB58_FA standard template (FMRIB; resolution: 1×1×1 mm3) in MNI152 space using FSL's non-linear registration tool (FNIRT v1.0).

Results

  • Relationship between CSF NfL and DTI metrics across ALS phenotypes.
  • Out of the whole sample n=29 classic ALS, n=14 LMND ALS and n=6 UMND ALS cases had available both, measures of CSF NfL and DTI metrics.
  • The distribution of observed survival times over measured NfL levels is shown in Supplemental Figure 3A for the distinct phenotypes.
  • The factor loads of [-0.7, 0.7] and [0.7, 0.7] lead to factor 1 describing constellations with low NfL values and comparatively longer survival times and factor 2 pointing to individuals with longer survival times despite higher NfL values.
  • One may thus hypothesize that these results point to the existence of distinct groups displaying high CSF NfL: UMND ALS with longer survival despite high CSF NfL and ALS patients with combined UMN and LMN pathology (classic disease phenotype), high CSF NfL and worse prognosis.

Subject code A1M1 A1M2 A2M1 A2M2

  • Unless otherwise reported, medians and are given.
  • ALS, amyotrophic lateral sclerosis; ALSFRS-R, revised ALS functional rating scale; LMND, lower motor neuron dominant; UMND, upper motor neuron dominant; *ANOVA, #binary logistic regression analysis.
  • P-values <0.05 were deemed to be statistically significant.

Figures

  • Availability of multimodal data in the ALS sample Constellations of data availability for the various measurements within the ALS sample.
  • CSF, clinical and genetic measures are colored in blue, measures to obtain PNS neuroaxonal injury are colored in green and measures to obtain CNS neuroaxonal injury are colored in orange.
  • Scatter plot of observed survival times vs. NfL measurement.

Did you find this useful? Give us your feedback

Content maybe subject to copyright    Report

Supplemental
Methods
ALS sample
Penn UMN score
The Penn UMN score ranged from 0 to 32 points and comprised items from the bulbar
segment (0-4 points) and from each of the four limbs (0-7 points per limb) [1]. In detail, for
the bulbar segment, single points were allocated for an abnormal jaw-jerk reflex, an
abnormal facial reflex, the existence of the palmomental sign and the existence of an
abnormal pseudobulbar affect. For the upper extremity subscore, single points were given for
each, pathologically brisk biceps reflex, triceps reflex, presence of finger flexors, Hoffmann’s
sign or the existence of a clonus anywhere in the limb. Additionally, spasticity was rated
according to the Ashworth Spasticity Scale (0-2 points, with adding 0 points for Ashworth 1
(normal tone), 1 point for Ashworth 2-3, 2 points for Ashworth 4-5) [2]. For the lower
extremity subscore, single points were allocated for each, pathologically brisk plantar reflex,
ancle reflex, crossed adduction, Babinski’s sign and a clonus anywhere in the limb. For the
lower extremity, spasticity was rated the same way as described for the upper extremity
subscore.
Clinical phenotypes
Clinical phenotypes were classified according to recent specifications [3, 4]. At the time of
study inclusion, a variable combination of UMN signs (spastic tone, clonus, etc.) and LMN
signs (wasting, weakness, fasciculations) in the upper and lower limbs were found in those
designated as classic ALS who, in turn, fulfilled the El Escorial criteria of definite or probable
ALS. UMND ALS patients had either no LMN signs, or, if present (1) they were restricted to
only 1 neuraxis level (bulbar, cervical, or lumbosacral); and (2) electromyographic
abnormalities were limited to sparse fibrillation potentials/positive sharp waves or minor
enlargement of motor unit potentials in 1 or at most 2 muscles [5, 6] for at least 12 months
after symptom onset. The diagnostic criteria for PLS required a period of at least 4 years in

which there were only UMN signs on examination. Other conditions that mimic PLS, such as
hereditary spastic paraplegia (HSP) were excluded by appropriate investigations [7]. All
patients with LMND ALS had clinical and electrophysiological evidence of sporadic
progressive pure LMN involvement in 1 or more regions without clinical signs of UMN
dysfunction. To differentiate this condition from early limb-onset ALS, we specified that LMN
involvement must be the predominant finding for at least 12 months after the symptom onset.
LMND ALS comprised patients with flail arm phenotype (n=4), flail leg phenotype (n=2) and
progressive muscular atrophy (n=3). Other LMN diseases, such as multifocal motor
neuropathy, spinal muscular atrophy, monomelic amyotrophy, Kennedy’s disease, and post-
polio syndrome, were excluded by extensive clinical and laboratory examinations [7, 8].
Data availability
CSF data were on hand for all ALS patients, of those 89 cases, 58 (69%) and 13 (15%)
patients, respectively, have already been included in our previous cross-sectional and
longitudinal peripheral nerve sonography ALS studies [3, 9, 10]. Out of the 84 patients with
available baseline ALSFRS-R scores, longitudinal ALSFRS-R scoring was performed in n=71
cases (80%) with at least two follow-ups and n=46 cases (52%) with at least three follow-ups.
Survival data could be identified in n=86 subjects (97%) with n=53 (62%) having died after a
median survival time of 35.8 months. C9orf72 and SOD1 status was available in n=64
patients (72%), comprising n=6 (9%) suffering from familial ALS (n=2 with C9orf72 positivity
and n=4 with SOD1 positivity). Nerve CSA was available in n=72 (81%) cases, CMAP
amplitudes in n=65 (73%) and MPRAGE images in n=61 (69%) subjects of whom n=51
(57%) had also cerebral DTI measures. Constellations of individual data availability in ALS
are indicated in Supplemental Figure 1.
CSF measures
Within 20 minutes of lumbar puncture, CSF samples were centrifuged at 4 C, aliquoted and
stored at -80 C until analysis. CSF biomarkers were measured with commercially available
ELISA (for NfL: NF-light® ELISA, IBL International GmbH, Hamburg, Germany; for total tau

[ttau] or ptau: Innotest hTauAg or Innotest p-Tau, Innogenetics, Ghent, Belgium), following
the instructions provided by the manufacturer.
To assess the performance of the NfL assay we determined the intra-assay coefficient of
variability (CV; =reproducibility, within-assay performance) and the inter-assay CV
(=repeatability, between-assay performance) [11]. CV was calculated using the root mean
square method, described e.g. in [19]. CSF samples of 2 controls and four ALS patients were
measured twice on the first assay, and procedure was repeated 24 hours later taking a
second assay. Intra-assay CV of duplicates was 3.1%, inter-assay CV was 10.6%, which is
in line with the literature [11]. Detailed CSF NfL values of each sample are given in
Supplemental Table 1.
3T MRI measures of the brain
All MRI scans were performed on the same Siemens Verio 3 T system (Siemens Medical
Systems, Erlangen, Germany) with a 32-channel head coil. 3D MPRAGE images were
acquired using the following parameters: acquisition time 9 min, 20 s, repetition time 2500
ms, echo time 4.82 ms, inversion time 1100 ms, flip angle 7 °, voxel size = 1×1×1 mm
3
. DWI
data were acquired with a resolution of 2×2×2 mm
3
. Diffusion gradients were applied along
30 non-collinear directions with b = 1000 s/mm
2
, one scan without diffusion weighting (b =
0 s/mm
2
) was also acquired. The data were averaged across two repetitions (for full details
see [12, 13]). A T2-weighted FLASH sequence was acquired during the same session to
investigate the presence of white matter hyperintensities.
Diffusion tensor imaging analysis
Diffusion tensor images were processed using the FMRIB software library (FSL [14];
Analysis Group, FMRIB, University of Oxford, UK). In brief, each diffusion weighted volume
was affined-aligned to its corresponding b0 image using FSL's linear image co-registration
tool (FLIRT v5.4.2) to correct for motion artifacts and eddy-current distortions. Using FSL’s
brain-extraction tool (BET v2.1) a binary brain mask of each b0 image was generated, with
fractional threshold f = 0.1 and vertical gradient g = 0. The original b-matrix was reoriented

using an in-house script to adjust it for rotations induced by the previous transformations.
FSL's diffusion toolbox (FDT v2.0) was used to fit a single tensor model, taking a weighted
linear approach, and to compute the maps of DTI scalars (FA, mean diffusivity (MD), radial
diffusivity (RD), axial diffusivity (AD)). Load of white matter lesion was evaluated on a T2-
weighted FLASH sequence employing the Fazekas scale [15].
The analyses were performed employing tract-based spatial statistics [16] that warped all the
FA images to the FMRIB58_FA standard template (FMRIB; resolution: 1×1×1 mm
3
) in
MNI152 space using FSL's non-linear registration tool (FNIRT v1.0). The warped FA maps
were averaged to create a mean FA template, from which the FA skeleton was computed,
imposing an FA threshold of 0.2. All the FA maps as well as the maps of the other DTI
scalars were then projected onto the skeleton. The whole-brain regression analysis was
conducted employing the Randomise tool version 2.9 available in FSL with 5000
permutations, threshold-free cluster enhancement (TFCE) and 2D optimization for tract-
based DTI analysis. The CST region of interest (ROI) analysis was performed using the CST
mask (bilateral) included in the JHU white matter tractography atlas available in FSL,
thresholded at 0.5. The JHU-CST mask was further intersected with the study- specific
skeleton and the resulting mask was used for extracting the median values of DTI scalars in
the CST for each participant.
Cortical thickness and volumetric measures
For each patient cortical thickness of the bilateral precentral gyrus was obtained from the
native-space MPRAGE scans using the automated FreeSurfer 6.0 parcellation [18]. Total
brain volume (TBV), GM volume (GMV) and WM volume (WMV), normalized for head size,
were estimated using the SIENAX algorithm from the SIENA-package of FSL v5.0.
Results
Relationship between CSF NfL and DTI metrics across ALS phenotypes

Out of the whole sample n=29 classic ALS, n=14 LMND ALS and n=6 UMND ALS cases had
available both, measures of CSF NfL and DTI metrics. Unfortunately, in our cohort the group
of LMND ALS and UMND ALS was too small, lacking the power to perform phenotype-wise
analysis. However, correlation between DTI metrics in the CST and NfL level was present
also when restricting the analysis to the classic ALS cases (NfL and FA: rho=-0.4, p=0.03;
NfL and RD: rho=0.4, p=0.05; Supplemental Figure 2). Results in classic ALS are
convincing, overall supporting our main findings of a significant relationship between CSF
NfL and CST integrity.
Relationship between CSF NfL and survival across ALS phenotypes
The distribution of observed survival times over measured NfL levels is shown in
Supplemental Figure 3A for the distinct phenotypes. Classic phenotypes with survival times
greater than 8 years were excluded as they seem to exhibit a somewhat different course of
disease. Within that plot, the distribution of the values of the UMND ALS phenotype is
seemingly different from that of the scatter pattern of the classic phenotype. To elucidate this,
a principal component analysis with the variables NfL and survival time was performed
yielding the eigenvectors shown as arrows in black. The factor loads of [-0.7, 0.7] and [0.7,
0.7] lead to factor 1 describing constellations with low NfL values and comparatively longer
survival times and factor 2 pointing to individuals with longer survival times despite higher
NfL values. The scatter plot in factor coordinates in Supplemental Figure 3B reveals that
patients with the classic phenotype tend to scatter along the factor 1 axis, displaying low NfL
and relatively long survival times or for negative factor 1 values a combination of high NfL
with short survival times. The UMND group displays a negative mean for factor 1, so that
they also seem to exhibit elevated NfL levels corresponding to decreased survival times. But
this is somewhat offset by a positive mean value in their factor 2 components, allowing for
constellations with higher NfL levels than comparably long-lived classic cases or the ability to
survive longer than would be expected for a classic case with these NfL levels (or a
combination of those two). One may thus hypothesize that these results point to the

Citations
More filters
Journal ArticleDOI
TL;DR: How NFs are impacting research and clinical management in ALS and other MNDs is discussed and how NFs may provide a useful tool for the early enrolment of patients in clinical trials is discussed.
Abstract: Motor neuron diseases (MNDs) are etiologically and biologically heterogeneous diseases. The pathobiology of motor neuron degeneration is still largely unknown, and no effective therapy is available. Heterogeneity and lack of specific disease biomarkers have been appointed as leading reasons for past clinical trial failure, and biomarker discovery is pivotal in today’s MND research agenda. In the last decade, neurofilaments (NFs) have emerged as promising biomarkers for the clinical assessment of neurodegeneration. NFs are scaffolding proteins with predominant structural functions contributing to the axonal cytoskeleton of myelinated axons. NFs are released in CSF and peripheral blood as a consequence of axonal degeneration, irrespective of the primary causal event. Due to the current availability of highly-sensitive automated technologies capable of precisely quantify proteins in biofluids in the femtomolar range, it is now possible to reliably measure NFs not only in CSF but also in blood. In this review, we will discuss how NFs are impacting research and clinical management in ALS and other MNDs. Besides contributing to the diagnosis at early stages by differentiating between MNDs with different clinical evolution and severity, NFs may provide a useful tool for the early enrolment of patients in clinical trials. Due to their stability across the disease, NFs convey prognostic information and, on a larger scale, help to stratify patients in homogenous groups. Shortcomings of NFs assessment in biofluids will also be discussed according to the available literature in the attempt to predict the most appropriate use of the biomarker in the MND clinic.

53 citations

Journal ArticleDOI
TL;DR: The evidence for NfL being a reliable biomarker in the early detection and disease management in several CNS-related disorders is summarized and the correlation between MRI and N fL is highlighted and asked whether they can be combined.
Abstract: The search for diagnostic and prognostic biomarkers for neurodegenerative conditions is of high importance, since these disorders may present difficulties in differential diagnosis. Biomarkers with high sensitivity and specificity are required. Neurofilament light chain (NfL) is a unique biomarker related to axonal damage and neural cell death, which is elevated in a number of neurological disorders, and can be detected in cerebrospinal fluid (CSF), as well as blood, serum, or plasma samples. Although the NfL concentration in CSF is higher than that in blood, blood measurement may be easier in practice due to its lesser invasiveness, reproducibility, and convenience. Many studies have investigated NfL in both CSF and serum/plasma as a potential biomarker of neurodegenerative disorders. Neuroimaging biomarkers can also potentially improve detection of CNS-related disorders at an early stage. Magnetic resonance imaging (MRI) and diffusion tensor imaging (DTI) are sensitive techniques to visualize neuroaxonal loss. Therefore, investigating the combination of NfL levels with indices extracted from MRI and DTI scans could potentially improve diagnosis of CNS-related disorders. This review summarizes the evidence for NfL being a reliable biomarker in the early detection and disease management in several CNS-related disorders. Moreover, we highlight the correlation between MRI and NfL and ask whether they can be combined.

47 citations

Journal ArticleDOI
TL;DR: There is mounting evidence that neurofilament light chain and phosphorylated neurofilaments are abnormal in a host of neurodegenerative diseases and what the authors know about how these biomarkers relate to in vivo white matter pathology and each other is examined.

40 citations

Journal ArticleDOI
TL;DR: In this article, the authors illustrate the significance of neurofilament light chain (NFL) as a biomarker for ALS and FTD and discuss unsolved issues and potential for future developments.
Abstract: Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two related currently incurable neurodegenerative diseases. ALS is characterized by degeneration of upper and lower motor neurons causing relentless paralysis of voluntary muscles, whereas in FTD, progressive atrophy of the frontal and temporal lobes of the brain results in deterioration of cognitive functions, language, personality, and behavior. In contrast to Alzheimer’s disease (AD), ALS and FTD still lack a specific neurochemical biomarker reflecting neuropathology ex vivo. However, in the past 10 years, considerable progress has been made in the characterization of neurofilament light chain (NFL) as cerebrospinal fluid (CSF) and blood biomarker for both diseases. NFL is a structural component of the axonal cytoskeleton and is released into the CSF as a consequence of axonal damage or degeneration, thus behaving in general as a relatively non-specific marker of neuroaxonal pathology. However, in ALS, the elevation of its CSF levels exceeds that observed in most other neurological diseases, making it useful for the discrimination from mimic conditions and potentially worthy of consideration for introduction into diagnostic criteria. Moreover, NFL correlates with disease progression rate and is negatively associated with survival, thus providing prognostic information. In FTD patients, CSF NFL is elevated compared with healthy individuals and, to a lesser extent, patients with other forms of dementia, but the latter difference is not sufficient to enable a satisfying diagnostic performance at individual patient level. However, also in FTD, CSF NFL correlates with several measures of disease severity. Due to technological progress, NFL can now be quantified also in peripheral blood, where it is present at much lower concentrations compared with CSF, thus allowing less invasive sampling, scalability, and longitudinal measurements. The latter has promoted innovative studies demonstrating longitudinal kinetics of NFL in presymptomatic individuals harboring gene mutations causing ALS and FTD. Especially in ALS, NFL levels are generally stable over time, which, together with their correlation with progression rate, makes NFL an ideal pharmacodynamic biomarker for therapeutic trials. In this review, we illustrate the significance of NFL as biomarker for ALS and FTD and discuss unsolved issues and potential for future developments.

34 citations

Journal ArticleDOI
TL;DR: Among all biomarkers, NfL yielded the highest diagnostic performance and was the best predictor of disease progression rate and survival in ALS and contribute to the understanding of the pathophysiological and electrophysiological correlates of biomarker changes.
Abstract: Neurofilament light chain protein (NfL) is currently the most accurate cerebrospinal fluid (CSF) biomarker in amyotrophic lateral sclerosis (ALS) in terms of both diagnostic and prognostic value, but the mechanism underlying its increase is still a matter of debate. Similarly, emerging CSF biomarkers of neurodegeneration and neuroinflammation showed promising results, although further studies are needed to clarify their clinical and pathophysiological roles. In the present study we compared the diagnostic accuracy of CSF NfL, phosphorylated (p)-tau/total (t)-tau ratio, chitinase-3-like protein 1 (YKL-40) and chitotriosidase 1 (CHIT1), in healthy controls (n = 43) and subjects with ALS (n = 80) or ALS mimics (n = 46). In ALS cases, we also investigated the association between biomarker levels and clinical variables, the extent of upper motor neuron (UMN) and lower motor neuron (LMN) degeneration, and denervation activity through electromyography (EMG). ALS patients showed higher levels of CSF NfL, YKL-40, CHIT1, and lower values of p-tau/t-tau ratio compared to both controls and ALS mimics. Among all biomarkers, NfL yielded the highest diagnostic performance (> 90% sensitivity and specificity) and was the best predictor of disease progression rate and survival in ALS. NfL levels showed a significant correlation with the extent of LMN involvement, whereas YKL-40 levels increased together with the number of areas showing both UMN and LMN damage. EMG denervation activity did not correlate with any CSF biomarker change. These findings confirm the highest value of NfL among currently available CSF biomarkers for the diagnostic and prognostic assessment of ALS and contribute to the understanding of the pathophysiological and electrophysiological correlates of biomarker changes.

29 citations

References
More filters
Journal ArticleDOI
TL;DR: Cerebrospinal fluid concentrations of tau, an axonal microtubule‐associated protein, have been measured in ALS with levels found increased in some studies and unchanged in others.
Abstract: Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder leading to progressive motor neuron cell death. Etiopathogenesis is still imperfectly known and much effort have been undertaken to find a biological marker that could help in the early diagnosis and in the monitoring of disease progression. Cerebrospinal fluid (CSF) concentrations of tau, an axonal microtubule-associated protein, have been measured in ALS with levels found increased in some studies and unchanged in others. Methods: Total CSF tau level was assayed in a population of ALS patients (n = 57) and controls (n = 110) using a specific ELISA method. Results: No significant differences in the median CSF tau levels between ALS cases and controls were found [ALS: 126 pg/ml (78–222); controls: 112 pg/ml (71–188), P = ns]. In the ALS group, the bulbar-onset patients showed increased CSF tau levels as compared with the spinal-onset cases. These differences might be related to the higher age of the bulbar-onset patients. Further, no correlations were found between CSF tau concentrations and the rate of progression of the disease. Conclusions: These results do not support the hypothesis that total CSF tau protein is a reliable biological marker for ALS.

30 citations


Additional excerpts

  • ...progression in ALS [12, 19, 21, 26], few studies indeed found a relationship between higher 135 CSF ttau or ptau at baseline and worse motor function [6, 23]....

    [...]

Journal ArticleDOI
TL;DR: In clinically pure LMND patients, the involvement of corticoefferent fibers was demonstrated, in particular along the CST, supporting the hypothesis that LMND is a phenotypical variant of ALS, and suggests to treat patients like ALS, including the opportunity to participate in clinical trials.
Abstract: Criteria for assessing upper motor neuron pathology in lower motor neuron disease (LMND) still remain major issues in clinical diagnosis. This study was designed to investigate patients with the clinical diagnosis of adult pure LMND by use of whole brain based diffusion tensor imaging (DTI) to delineate alterations of corticoefferent pathways in vivo. Comparison of fractional anisotropy (FA) maps was performed by whole brain-based spatial statistics for 37 LMND patients vs. 53 matched controls to detect white matter structural alterations. LMND patients were clinically differentiated in fast and slow progressors. Furthermore, tract specific alterations were investigated by fiber tracking techniques according to the staging hypothesis for amyotrophic lateral sclerosis (ALS). The analysis of white matter structural connectivity demonstrated widespread and characteristic patterns of alterations in patients with LMND, predominantly along the corticospinal tract (CST), with multiple clusters of regional FA reductions in the motor system at p < 0.05 (corrected for multiple comparisons). Fast progressing LMND showed substantial CST involvement, while slow progressors showed less CST alterations. In the tract-specific analysis according to the ALS-staging pattern as suggested by Braak, fast progressing LMND showed significant alterations of ALS-related tract systems beyond the CST compared to slow progressors and controls. In clinically pure LMND patients, the involvement of corticoefferent fibers was demonstrated, in particular along the CST, supporting the hypothesis that LMND is a phenotypical variant of ALS. This finding suggests to treat these patients like ALS, including the opportunity to participate in clinical trials.

28 citations

Journal ArticleDOI
TL;DR: Clinical measures combined with assessment of cortical function established that SICI decreased with disease progression, suggesting dysfunction of inhibitory interneurons with disease progress.

26 citations


"Significance of CSF NfL and tau in ..." refers background in this paper

  • ...potential (CMAP) amplitudes [31, 32] and sonographic cross-sectional nerve area (CSA) [29, 163 33] (for methodological details of PNS measures see [29]), precentral gyrus thickness, 164 cortical and subcortical cerebral gray matter (GM) volumes and CST DTI metrics (e....

    [...]

Journal ArticleDOI
TL;DR: This article reviews the published literature regarding brain-specific CSF markers for cytoskeletal damage in primary progressive multiple sclerosis and amyotrophic lateral sclerosis in order to evaluate their utility as a biomarker for disease progression in conjunction with imaging and histological markers.
Abstract: Many neurodegenerative disorders share a common pathophysiological pathway involving axonal degeneration despite different etiological triggers. Analysis of cytoskeletal markers such as neurofilaments, protein tau and tubulin in cerebrospinal fluid (CSF) may be a useful approach to detect the process of axonal damage and its severity during disease course. In this article, we review the published literature regarding brain-specific CSF markers for cytoskeletal damage in primary progressive multiple sclerosis and amyotrophic lateral sclerosis in order to evaluate their utility as a biomarker for disease progression in conjunction with imaging and histological markers which might also be useful in other neurodegenerative diseases associated with affection of the upper motor neurons. A long-term benefit of such an approach could be facilitating early diagnostic and prognostic tools and assessment of treatment efficacy of disease modifying drugs.

21 citations


Additional excerpts

  • ...progression in ALS [12, 19, 21, 26], few studies indeed found a relationship between higher 135 CSF ttau or ptau at baseline and worse motor function [6, 23]....

    [...]

Journal ArticleDOI
TL;DR: Various cerebrospinal fluid biomarkers are being studied to improve the sensitivity and specificity of the diagnostic methods for amyotrophic lateral sclerosis (ALS).
Abstract: Background Various cerebrospinal fluid (CSF) biomarkers are being studied to improve the sensitivity and specificity of the diagnostic methods for amyotrophic lateral sclerosis (ALS). Aims of the study The aim of our study was to establish the CSF levels of chromogranin A (CgA) and phosphorylated neurofilament heavy chain (pNF-H) in patients with ALS in order to assess these proteins as possible biomarkers of ALS. Methods Cerebrospinal fluid levels of CgA and pNF-H were examined and mutually compared in 15 patients with sporadic ALS and 16 gender- and age-matched controls. Results Lumbar CSF CgA levels were increased in the patients with ALS compared to the controls (median 235 vs 138, P=.031). Lumbar CSF pNF-H levels were significantly increased in the patients with ALS compared to the control group (median 3091 vs 213, P Conclusions Identifying CSF biomarkers in ALS is important in order to establish the diagnosis in the early stages of the disease. pNF-H seems to be a good biomarker for the diagnosis of ALS. If confirmed on a larger group of patients, CgA may also become useful in the diagnosis of sporadic ALS.

12 citations

Related Papers (5)
Frequently Asked Questions (1)
Q1. What are the contributions in this paper?

The Penn UMN score ranged from 0 to 32 points and comprised items from the bulbar segment ( 0-4 points ) and from each of the four limbs ( 0 -7 points per limb ) this paper.